25 patents
Utility
Erythropoietin and Analogs for Veterinary Use
28 Dec 23
Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals.
Hangjun Zhan, Lam Nguyen, Yongzhong Li, Qingyi Chu, Estela Garcia-Murillo, Victoria Leitman, Stephen Sundlof, Richard Chin, Shyr Jiann Li
Filed: 30 May 23
Utility
ANTI-IL31 Antibodies for Veterinary Use
16 Nov 23
Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31.
Shyr Jiann LI, Lam NGUYEN, Hangjun ZHAN
Filed: 24 May 23
Utility
Long-acting ANTI-IL31 Antibodies for Veterinary Use
5 Oct 23
Provided are various embodiments relating to long-acting anti-IL31 antibodies binding to canine IL31 and/or feline IL31.
Shyr Jiann LI, Lam NGUYEN, Qingyi CHU, Richard CHIN, Hangjun ZHAN
Filed: 22 Apr 21
Utility
Anti-IL31 antibodies for veterinary use
11 Jul 23
Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31.
Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
Filed: 30 Sep 20
Utility
Equine Esomeprazole Formulations and Methods of Use
10 Nov 22
The present disclosure relates to formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium or esomeprazole magnesium dihydrate, and methods of use in treating ulcers in equines and other veterinary animals The disclosure also relates to injectable formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium, or esomeprazole magnesium dihydrate, which have a small particle size, such as a median particle size of less than 10 μm or less than 5 μm.
Geeta Srivastava, Om P. Srivastava, Emily Sundman, Melinda Poole O'Banion
Filed: 15 Jul 20
Utility
Anti-IL31 Antibodies for Veterinary Use
13 Oct 22
Provided are various embodiments relating to anti-IL31 antibodies having enhanced binding to canine IL31 and feline IL31.
Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
Filed: 28 Aug 20
Utility
Parvovirus Antibodies for Veterinary Use
25 Aug 22
Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics.
Hangjun Zhan, Lam Nguyen, Ellen Ratcliff, Richard Chin, Shyr Jiann Li
Filed: 30 Jul 20
Utility
IL17A Antibodies and Antagonists for Veterinary Use
16 Jun 22
Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A.
Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
Filed: 4 Mar 22
Utility
NGF Antagonists for Medical Use
2 Jun 22
Provided are various embodiments relating to TrkA ECD polypeptides from companion animal species that bind to NGF.
Hangjun Zhan, Lam Nguyen, Richard Chin, Fawn Qian, Shyr Jiann Li, Qingyi Chu
Filed: 20 Mar 20
Utility
IGG FC Variants for Veterinary Use
3 Mar 22
Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD 16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins.
Hangjun Zhan, Lam Nguyen, Yongzhong Li, Fawn Qian, Shyr Jiann Li, Richard Chin
Filed: 26 Dec 19
Utility
Anti-IL4 Receptor Antibodies for Veterinary Use
17 Feb 22
Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R.
Shyr Jiann Li, Lam Nguyen, Richard Chin, Hangjun Zhan
Filed: 14 Sep 19
Utility
Erythropoietin Analogs For Veterinary Use
27 Jan 22
Provided are various embodiments relating to erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and/or additional cysteine residues and methods of producing and using the same to treat anemia in companion animals.
Hangjun Zhan, Lam Nguyen, Qingyi Chu, Shyr Jiann Li
Filed: 12 Dec 19
Utility
IL4/IL13 Receptor Molecule for Veterinary Use
23 Dec 21
Provided are various embodiments relating to IL13R/IL4R heterodimeric proteins derived from companion animal species and that bind to IL13 and/or IL4.
Hangjun Zhan, Lam Nguyen, Fawn Qian, Shyr Jiann Li
Filed: 24 Oct 19
Utility
Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
16 Dec 21
Provided are various embodiments relating to variant IgG Fc polypeptides with altered FcRn binding activity.
Hangjun Zhan, Lam Nguyen, Qingyi Chu, Richard Chin, Shyr Jiann Li
Filed: 18 Oct 19
Utility
Anti-IL31 Antibodies for Veterinary Use
3 Jun 21
Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31.
Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
Filed: 30 Sep 20
Utility
Variant Asparaginase Polypeptides for Medical Use
4 Mar 21
Provided are various embodiments relating to variant asparaginase polypeptides with enhanced stability, pharmacodynamics, and/or reduced immunogenicity.
Hangjun Zhan, Lam Nguyen, Richard Chin, Shyr Jiann Li
Filed: 18 Apr 19
Utility
Erythropoietin and Analogs for Veterinary Use
4 Feb 21
Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals.
Hangjun Zhan, Lam Nguyen, Yongzhong Li, Qingyi Chu, Estela Garcia-Murillo, Victoria Leitman, Stephen Sundlof, Richard Chin, Shyr Jiann Li
Filed: 5 Jun 18
Utility
IgG Fc Variants for Veterinary Use
18 Nov 20
Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction, increased stability, and/or the ability to form heterodimeric proteins.
Hangjun Zhan, Lam Nguyen, Yongzhong Li, Fawn Qian, Shyr Jiann Li
Filed: 14 Aug 18
Utility
Compositions and Methods for Treatment and Prevention of Pyrexia in Horses
21 Oct 20
Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.
Emily Sundman
Filed: 6 May 20
Utility
IL17A Antibodies and Antagonists for Veterinary Use
24 Jun 20
Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A.
Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
Filed: 17 Jun 18